Brief: Solid Biosciences Doses First Participant In First-In-Class Phase 1B Falcon Trial Evaluating Sgt-212 Dual-Route Gene Therapy For The Treatment Of Friedreich’S Ataxia
12/01/2026 13:06
Jan 12 (Reuters) - Solid Biosciences Inc SLDB.O: SOLID BIOSCIENCES DOSES FIRST PARTICIPANT IN FIRST-IN-CLASS PHASE 1B FALCON TRIAL EVALUATING SGT-212 DUAL-ROUTE GENE THERAPY FOR THE TREATMENT OF FRIEDREICH’S ATAXIA SOLID BIOSCIENCES INC: EXPECT TO SHARE AN INITIAL DATA UPDATE IN SECOND HALF OF 2026 Source text: ID:nGNXN0Kp0 Further company coverage: SLDB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Solid Biosciences
See all newsSolid Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Solid Biosciences Inc expected to post a loss of 48 cents a share - Earnings Preview
Solid Biosciences Q2 net loss widens on higher R&D costs
Marketing Agreement To Advance Gene Therapy Delivery And Analytics
Solid Biosciences Q1 net loss widens on higher R&D costs